Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of Pharma-Bio Serv, Inc. from 31 Oct 2020 to 31 Jul 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Pharma-Bio Serv, Inc. quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 31 Oct 2020 to 31 Jul 2025.
  • Pharma-Bio Serv, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Jul 2025 was $1,864,677, a 38% decline year-over-year.
  • Pharma-Bio Serv, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the twelve months ending 31 Jul 2025 was $2,562,430, a 170% decline year-over-year.
  • Pharma-Bio Serv, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $3,678,698, a 8.4% increase from 2023.
  • Pharma-Bio Serv, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $4,016,675, a 34% decline from 2022.
  • Pharma-Bio Serv, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was $3,005,616, a 1010% decline from 2021.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Trailing 12 Months (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

Pharma-Bio Serv, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $2,562,430 $1,864,677 -$1,146,096 -38% 01 May 2025 31 Jul 2025 10-Q 15 Sep 2025 2025 Q3
Q1 2025 $1,416,334 $5,214,048 -$2,309,907 -80% 01 Feb 2025 30 Apr 2025 10-Q 16 Jun 2025 2025 Q2
Q4 2024 $893,573 $539,767 +$4,572,271 01 Nov 2024 31 Jan 2025 10-Q 17 Mar 2025 2025 Q1
Q3 2024 $3,678,698 $247,174 -$7,329,296 -97% 01 Aug 2024 31 Oct 2024 10-K 29 Jan 2025 2024 FY
Q2 2024 $3,650,598 $3,010,773 +$8,237,643 01 May 2024 31 Jul 2024 10-Q 15 Sep 2025 2025 Q3
Q1 2024 $4,587,045 $2,904,141 -$3,775,345 -433% 01 Feb 2024 30 Apr 2024 10-Q 16 Jun 2025 2025 Q2
Q4 2023 $811,700 $4,032,504 +$3,204,975 +44% 01 Nov 2023 31 Jan 2024 10-Q 17 Mar 2025 2025 Q1
Q3 2023 $4,016,675 $7,576,470 +$7,352,570 +3284% 01 Aug 2023 31 Oct 2023 10-K 29 Jan 2025 2024 FY
Q2 2023 $11,369,245 $5,226,870 -$6,301,702 -586% 01 May 2023 31 Jul 2023 10-Q 16 Sep 2024 2024 Q3
Q1 2023 $5,067,543 $871,204 +$3,058,760 01 Feb 2023 30 Apr 2023 10-Q 14 Jun 2024 2024 Q2
Q4 2022 $8,126,303 $7,237,479 -$5,120,687 -242% 01 Nov 2022 31 Jan 2023 10-Q 18 Mar 2024 2024 Q1
Q3 2022 $3,005,616 $223,900 -$746,275 -77% 01 Aug 2022 31 Oct 2022 10-K 29 Jan 2024 2023 FY
Q2 2022 $2,259,341 $1,074,832 +$643,149 +149% 01 May 2022 31 Jul 2022 10-Q 14 Sep 2023 2023 Q3
Q1 2022 $2,902,490 $2,187,556 +$734,296 +25% 01 Feb 2022 30 Apr 2022 10-Q 14 Jun 2023 2023 Q2
Q4 2021 $3,636,786 $2,116,792 -$3,967,207 -214% 01 Nov 2021 31 Jan 2022 10-Q 17 Mar 2023 2023 Q1
Q3 2021 $330,421 $970,175 01 Aug 2021 31 Oct 2021 10-K 30 Jan 2023 2022 FY
Q2 2021 $431,683 01 May 2021 31 Jul 2021 10-Q 14 Sep 2022 2022 Q3
Q1 2021 $2,921,852 01 Feb 2021 30 Apr 2021 10-Q 14 Jun 2022 2022 Q2
Q4 2020 $1,850,415 01 Nov 2020 31 Jan 2021 10-Q 17 Mar 2022 2022 Q1

Pharma-Bio Serv, Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,678,698 +$337,977 +8.4% 01 Nov 2023 31 Oct 2024 10-K 29 Jan 2025 2024 FY
2023 $4,016,675 -$1,011,059 -34% 01 Nov 2022 31 Oct 2023 10-K 29 Jan 2025 2024 FY
2022 $3,005,616 -$3,336,037 -1010% 01 Nov 2021 31 Oct 2022 10-K 29 Jan 2024 2023 FY
2021 $330,421 -$1,317,329 -80% 01 Nov 2020 31 Oct 2021 10-K 30 Jan 2023 2022 FY
2020 $1,647,750 01 Nov 2019 31 Oct 2020 10-K 11 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.